{"name": "gefapixant", "category": "drug", "content": "Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor. It was approved for medical use in the European Union in September 2023.   == Medical uses == Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.   == Society and culture ==   === Names === It was named in honour of Geoff Burnstock.   == References =="}